Drug Profile

AX 202

Alternative Names: AX-202

Latest Information Update: 17 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arxx Therapeutics
Developer Calluna Pharma
Class Antifibrotics; Antipsoriatics; Monoclonal antibodies
Mechanism of Action S100 calcium-binding protein A4 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Plaque psoriasis
Preclinical Systemic scleroderma
Research Unspecified

Most Recent Events

17 May 2025 Adverse event, pharmacokinetics and pharmacodynamics data from a phase I trial in Plaque psoriasis presented at the 121^st International Conference of the American Thoracic Society (ATS-2025)
23 Jan 2024 Oxitope Pharma has merged with Arxx Therapeutics to form Calluna Pharma
30 Nov 2022 Phase-I clinical trials in Plaque psoriasis in United Kingdom (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com